NDAVAGINALSUPPOSITORY
Approved
Aug 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
CLEOCIN (clindamycin phosphate) by Pfizer is clinical pharmacology mechanism of action clindamycin is an antibacterial drug (see). First approved in 1999.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLEOCIN (clindamycin phosphate) is a lincosamide antibiotic vaginal suppository approved in 1999 for bacterial vaginosis and related infections. It works by inhibiting bacterial protein synthesis, with only 30% systemic absorption when administered intravaginally, resulting in substantially lower systemic exposure than oral or parenteral formulations. The suppository delivers localized therapeutic effect with minimal systemic toxicity.
$0.166MPart D
LOE ApproachingDeclining
Product is in LOE-approaching phase with minimal Part D claims; expect brand team contraction and focus shift to retention strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Clindamycin is an antibacterial drug (See). Pharmacokinetics Systemic absorption of clindamycin was estimated following a once-a-day intravaginal dose of one clindamycin phosphate vaginal suppository (equivalent to 100 mg clindamycin) administered to 11…
Indications
Worked on CLEOCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.